ITCI - intracellulartherapies.com Projected Price to Earnings
Strategic alliances with clinics and streamlined distribution in the US ensure the accessibility of Caplyta therapy for Intra-Cellular Therapies (ITCI). The forward P/E multiple for Intra-Cellular Therapies (ITCI) demonstrates the impact of regulatory policy on market value, while 29.00 expresses the current value of the metric. The creation of benchmark schizophrenia treatments guarantees stable demand for drugs used in treating chronic disorders for many years.
ITCI (Intra-Cellular): analytical breakdowns and indicator data
- stock value and consensus price forecast:
- market capitalization statistics:
- issuer book value statistics:
- debt and solvency information:
Total Debt to Equity Ratio Intra-Cellular Therapies|ITCI - Long-Term Indebtedness to Equity|Short-Term Debt to Capital Intra-Cellular Therapies|ITCI - Company Total Debt|Debts to Book Capitalization Intra-Cellular Therapies Inc.|ITCI - Long-Term Debt|Company Short-Term Debt Intra-Cellular Therapies|Quick Liquidity intracellulartherapies.com
- company profitability and valuation multiples indicators:
ITCI - Company Net Income|Future Profit Intra-Cellular Therapies|ITCI - P/E Multiple|Future Price to Earnings Intra-Cellular Therapies|ITCI - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Intra-Cellular Therapies Inc.|ITCI - Operating profit EBITDA|Earnings per share for the last twelve months Intra-Cellular Therapies|ITCI - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months intracellulartherapies.com|ITCI - Earnings per share increase in current year|Expected earnings per share growth for next year Intra-Cellular Therapies
- sales volume and revenue information:
Fundamental company analysis:Intra-Cellular Therapies, Inc.
The success of the Intra-Cellular Therapies (ITCI) blockbuster in treating psychiatric disorders and its patent protection allow for the valuation of ITCI through the lens of expected earnings. By analyzing the company's historical forward P/E ratio, an investor can compare the current share price with projected net income, which helps determine the fairness of the market price and the asset's growth potential amidst competition.
Competitors of Intra-Cellular Therapies (ITCI)
Future Price to Earnings Biogen (BIIB)|Neurocrine - Price to Future Earnings Ratio|Regencell - Projected Price to Earnings|Market Cap to Future Earnings Ratio AXSM (Axsome Corp)|ACAD - Future Price to Earnings|Future Price to Earnings Multiple XENE (xenon-pharma.com)|VKTX: Forward P/E Multiple|Supernus Pharmaceuticals, Inc. (SUPN) - Forward P/E Multiple|Projected Price to Earnings CPRX|DNLI - Forward Price to Earnings Multiple|Forward P/E Multiple HRMY|Projected Price to Earnings biohavenpharma.com BHVN|Forward P/E Multiple AMLX (Amylyx Pharmaceuticals, Inc.)|Trevi Therapeutics Inc (TRVI) - Projected Price to Earnings Ratio|PRAX - Future Price to Earnings|AVXL: Future Price to Earnings|CeriBell, Inc. (CBLL) - Future Price to Earnings|PRTA (Prothena) - Future Price to Earnings|Projected Price to Earnings ALEC|Forward P/E Multiple Annexon Biosciences|Future Price to Earnings Omeros Corporation (OMER)|Future Price to Earnings NGNE (Neurogene Therapeutics)|Forward P/E Multiple ACIU (AC Immune)|Forward P/E Multiple voyagertherapeutics.com VYGR|NMRA - Future Price to Earnings|Future Price to Earnings Multiple SCLX (Scilex Holding)|TVGN (Tevogen Bio Holdings, Inc.) - Projected Price to Earnings|Alpha Cognition Inc. - Future Price to Earnings Multiple|Projected Price to Earnings CGTX|IKT (inhibikase.com) - Market Cap to Future Earnings Ratio|Forward P/E Multiple SAVA|ASRT (assertiotx.com) - Future Price to Earnings Multiple|Forward P/E Multiple COYA (Coya Therapeutics)|VistaGen Therapeutics, Inc. (VTGN) - Projected Price to Earnings Ratio|OVID - Future Price to Earnings|Future Price to Earnings Multiple ABOS (acumenpharm.com)|CRVO: Forward P/E Multiple|Alterity Therapeutics Limited (ATHE) - Forward P/E Multiple|Future Price to Earnings Clene Inc|PepGen Corp - Price to Expected Earnings Ratio|Forward P/E Multiple JUNS|Market Cap to Projected Earnings relmada.com|Forward P/E Multiple ANVS (Annovis Bio)|Grace Therapeutics Inc (GRCE) - Projected Price to Earnings Ratio|AIFF - Future Price to Earnings|Market Cap to Projected Earnings Klotho Neurosciences Inc KLTO|NRSN: Forward P/E Multiple|RVPH - Market Cap to Projected Earnings|Projected Price to Earnings MTVA|NRXS (NeurAxis Inc.) - Market Cap to Future Earnings Ratio|Forward P/E Multiple HSDT|Projected Price to Earnings passagebio.com PASG|Forward P/E Multiple NEUP (Neuphoria Therapeutics)|Market Cap to Projected Earnings minervaneurosciences.com (NERV)|ATHA - Future Price to Earnings|ADXN (Addex Therapeutics Ltd.) - Price to Future Earnings Ratio|ALZN: Forward P/E Multiple|Projected Price to Earnings Ratio Cyclerion Therapeutics, Inc. (CYCN)|Projected Price to Earnings PTIX|Forward P/E Multiple Pasithea|Future Price to Earnings Cortigent, Inc. (CRGT)|ATXI (Avenue Therapeutics Inc.) - Future Price to Earnings Multiple|Future Price to Earnings Brainstorm Cell Therapeutics, Inc. BCLI|Cara Therapeutics Inc (CARA) - Projected Price to Earnings Ratio|Chromocell Therapeutics - Forward P/E Multiple|Market Cap to Projected Earnings Eliem Therapeutics ELYM|Longboard Pharmaceuticals, Inc. (LBPH) - Future Price to Earnings|Price to Future Earnings Ratio MRNS|Projected Price to Earnings NKGN|NRBO (NeuroBo Pharma) - Market Cap to Future Earnings Ratio|Future Price to Earnings Sage Therapeutics, Inc. (SAGE)|SNPX (synaptogen.com) - Future Price to Earnings Multiple|Forward P/E Multiple TRVN (Trevena)|Forward P/E Multiple Vigil Neuroscience Inc. VIGL|WENA: Projected Price to Earnings|Forward Price to Earnings Multiple Cerevel Corp (CERE)
